Skip to main
CTSO

CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents (CTSO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

CytoSorbents Corp has demonstrated a strong financial performance with fourth-quarter gross margins expanding to an expected range of 73% to 75% and a full-year gross margin improvement to approximately 72%, indicating effective operational leverage and manufacturing efficiencies. The company reported $9.5 million in revenue for the fourth quarter, reflecting a 10% year-over-year increase, fueled by distributor-driven revenue growth and advancements in product development, particularly with DrugSorb-ATR. Additionally, the management's proactive balance sheet strategies, including a credit agreement amendment to enhance liquidity, alongside strong clinical data supporting its products, position CytoSorbents favorably for sustained growth and profitability.

Bears say

CytoSorbents Corp reported fourth quarter revenue of approximately $9.2 million, reflecting flat year-over-year performance, while full-year revenue reached around $37.0 million, indicating only 4% growth from the prior year. Management has pointed to patient imbalances in the initial U.S. market, suggesting operational challenges that could impede revenue growth. Furthermore, the company's shares are perceived to be trading at a distressed valuation, which analysts attribute to factors largely unrelated to the company's fundamental performance.

CytoSorbents (CTSO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytoSorbents (CTSO) Forecast

Analysts have given CytoSorbents (CTSO) a Buy based on their latest research and market trends.

According to 2 analysts, CytoSorbents (CTSO) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytoSorbents (CTSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.